Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | MGLL | Q99685 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5714513 | 0.93 | MAPT (0.38) | KMT2AALDH1A1MAPTPOLB | |
| SCHEMBL5714995 | 0.92 | SIGMAR1 (0.42) | KMT2AALDH1A1MAPTMGLL | |
| SCHEMBL5715317 | 0.92 | SMN1; SMN2 (0.46) | KMT2AALDH1A1KDM4EPOLBMGLL | |
| SCHEMBL5715045 | 0.89 | ALDH1A1 (0.49) | KMT2AALDH1A1KDM4EMAPT | |
| SCHEMBL5714153 | 0.86 | MAPT (0.39) | KMT2AALDH1A1MAPTPOLB | |
| SCHEMBL5715066 | 0.86 | SMN1; SMN2 (0.45) | KMT2AALDH1A1KDM4EPOLB | |
| SCHEMBL5715227 | 0.85 | KDM4E (0.47) | KMT2AALDH1A1KDM4EMGLL | |
| SCHEMBL5714896 | 0.85 | MAPT (0.39) | KMT2AALDH1A1MAPTPOLBMGLL | |
| SCHEMBL5714332 | 0.85 | MAPT (0.38) | KMT2AALDH1A1KDM4EMAPTMGLL | |
| SCHEMBL5714612 | 0.84 | CYP1A2 (0.42) | KMT2AALDH1A1KDM4EMGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060160820-A1 | Substituted piperazine carbamates | NOVO NORDISK A/S (DK) | 2006-07-20 | — | — | US | claimed |
| US-20060160820-A1 | Substituted piperazine carbamates | NOVO NORDISK A/S (DK) | 2006-07-20 | — | — | US | disclosed |
| EP-1636187-A1 | SUBSTITUTED PIPERAZINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE | NOVO NORDISK A/S (DK) | 2006-03-22 | — | — | EP | disclosed |
| WO-2004111004-A1 | SUBSTITUTED PIPERAZINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE | NOVO NORDISK A/S (DK) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160820-A1 | Substituted piperazine carbamates | LIPE, PNLIP, LPL | KMT2A 1677/4885ALDH1A1 1504/4885KDM4E 1090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.